公开(公告)号：US10010595B2

公开(公告)日：2018-07-03

申请号：US14520163

申请日：2014-10-21

申请人： The Regents of the University of California

发明人： Marcus A. Horwitz ,  Qingmei Jia

IPC分类号： A61K39/02 ,  C07K14/35 ,  C07K14/195 ,  A61K39/04 ,  C12N1/20 ,  C12N1/36 ,  A61K39/00

CPC分类号： A61K39/02 ,  A61K39/04 ,  A61K2039/522 ,  A61K2039/523 ,  A61K2039/545 ,  A61K2039/5555 ,  A61K2039/55566 ,  A61K2039/6037 ,  C07K14/195 ,  C07K14/35 ,  C07K2319/40 ,  C12N1/20 ,  C12N1/36

摘要： Embodiments of the invention comprise an improved vaccine for generating an immune response and preventing or treating mycobacterial diseases such as tuberculosis in humans and animals. Embodiments of the invention also comprise a method for using the vaccine against such mycobacterial diseases.

公开(公告)号：US09926346B2

公开(公告)日：2018-03-27

申请号：US14394689

申请日：2012-04-16

申请人： John Fulkerson ,  Michael Brennan ,  Kamalakannan Velmurugan ,  Camille Locht

发明人： John Fulkerson ,  Michael Brennan ,  Kamalakannan Velmurugan ,  Camille Locht

IPC分类号： C07K14/35 ,  A61K39/04 ,  A61K49/00 ,  A61K39/00

CPC分类号： C07K14/35 ,  A61K39/04 ,  A61K49/0006 ,  A61K2039/523 ,  A61K2039/53 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/40 ,  C07K2319/90

摘要： Recombinant Mycobacteria (rMyc) which contain sequences encoding a heparin-binding hemagglutinin (HBHA) fusion protein are provided, as are methods of making and using the rMyc and the fusion protein. The fusion protein includes an amino terminal mycobacterial antigen Ag85B leader peptide and transcription of the fusion protein is driven by an Ag85B promoter sequence. The recombinant fusion protein is produced in abundance by the rMyc, is post-translationally methylated, and is highly antigenic.

公开(公告)号：US09925257B2

公开(公告)日：2018-03-27

申请号：US14604215

申请日：2015-01-23

申请人： The Forsyth Institute

发明人： Antonio Campos-Neto ,  Mark Cayabyab ,  Margaret Duncan

IPC分类号： A61K39/02 ,  A61K39/00 ,  A61K39/08 ,  A61K39/21 ,  A61K39/04 ,  C07K14/33 ,  C07K14/35 ,  C07K14/005 ,  A61K45/06 ,  C07K14/315 ,  A61K39/12 ,  C12N9/24

CPC分类号： A61K39/21 ,  A61K39/04 ,  A61K39/08 ,  A61K39/12 ,  A61K45/06 ,  A61K2039/523 ,  A61K2039/541 ,  A61K2039/545 ,  A61K2039/58 ,  C07K14/005 ,  C07K14/315 ,  C07K14/33 ,  C07K14/35 ,  C07K2319/02 ,  C07K2319/21 ,  C07K2319/40 ,  C07K2319/55 ,  C12N9/2402 ,  C12N2740/15022 ,  C12N2740/15033 ,  C12N2740/16033 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2740/16171

摘要： The present invention relates to a new vaccine delivery system. In particular, the present invention includes compositions and methods of integrally transformed non-pathogenic, commensal bacteria that can express a nucleic acid molecule of a foreign polypeptide, wherein the nucleic acid molecule that encodes the foreign polypeptide is stably integrated into genomic DNA of the bacteria. The foreign polypeptide includes a vaccine antigen that elicits an immunogenic response, an inhibitor of a pathogen, or an immune booster or modulator.

公开(公告)号：US20180064798A1

公开(公告)日：2018-03-08

申请号：US15645760

申请日：2017-07-10

申请人： Markus Maeurer

发明人： Markus Maeurer

IPC分类号： A61K39/04 ,  C12Q1/48 ,  C12N15/117

CPC分类号： A61K39/04 ,  A61K2039/522 ,  C07K14/35 ,  C12N15/117 ,  C12Q1/48

摘要： The present invention provides new immunological compositions and vaccines comprising selected M. tuberculosis antigens and antigenic peptides as well as nucleic acids encoding said antigens for use in the prevention, prophylaxis and treatment of mycobacterial infection, especially tuberculosis. In particular the invention provides recombinant BCG based vaccines in which one or more of the selected M. tuberculosis antigens are over expressed. The invention further provides isolated peptides for use in methods for diagnosing, characterizing, or classifying mycobacterial infections.

公开(公告)号：US20170356037A9

公开(公告)日：2017-12-14

申请号：US15308206

申请日：2015-05-01

申请人： Oxford Nanopore Technologies Ltd.

发明人： James Anthony Clarke ,  Andrew John Heron ,  Lakmal Jayasinghe ,  Elizabeth Jayne Wallace

IPC分类号： C12Q1/68 ,  C07K14/35

CPC分类号： C12Q1/6869 ,  C07K14/35 ,  C12Q2563/157 ,  C12Q2565/631

摘要： The invention relates to mutant forms of Msp. The invention also relates to polynucleotide characterisation using Msp.

公开(公告)号：US09821047B2

公开(公告)日：2017-11-21

申请号：US14473322

申请日：2014-08-29

申请人： Longhorn Vaccines and Diagnostics, LLC

发明人： Gerald W. Fischer ,  Luke T. Daum ,  Clara Jebet Sei

IPC分类号： C07K16/00 ,  A61K39/04 ,  C07K16/12 ,  A61K39/40 ,  C07K14/35 ,  G01N33/50 ,  A61K39/12 ,  A61K39/00

CPC分类号： A61K39/04 ,  A61K39/12 ,  A61K39/40 ,  A61K2039/521 ,  A61K2039/55505 ,  A61K2039/55566 ,  A61K2039/575 ,  A61K2039/6037 ,  A61K2039/6081 ,  A61K2039/70 ,  C07K14/35 ,  C07K16/1289 ,  C07K2317/73 ,  C07K2319/00 ,  C07K2319/31 ,  C12N2760/16134 ,  G01N33/5055

摘要： The invention is directed to compositions and methods for generating or enhancing the immune system of a patient against infection by a pathogen, and in particular MTB. Compositions of the invention contain one or more non-naturally occurring antigens that generate an effective cellular or humoral immune response to MTB and/or antibodies that are specifically reactive to mycolic acid or to the surface of MTB. The greater activity of the immune system generated by a vaccine of the invention involve an conjugation of peptides to increase in the generation of memory T cells that provide for a greater and/or longer lived or extended response to an MTB infection. Preferably a response involves an increased generation of antibodies that enhance immunity against MTB infection and promote an enhanced phagocytic response.

公开(公告)号：US09782495B2

公开(公告)日：2017-10-10

申请号：US15335920

申请日：2016-10-27

申请人： Rutgers, The State University of New Jersey

发明人： Maria Laura Gennaro

IPC分类号： A61K39/04 ,  A61K39/02 ,  A61K39/00 ,  A61K49/00 ,  C07K14/35 ,  G01N33/569 ,  G01N33/50 ,  A61K38/00

CPC分类号： A61K49/0006 ,  A61K38/00 ,  A61K39/00 ,  A61K39/04 ,  A61K2039/53 ,  C07K14/35 ,  G01N33/5091 ,  G01N33/5695 ,  G01N2333/35 ,  G01N2333/57 ,  G01N2800/26 ,  Y10S435/863

摘要： The present invention is directed to reagents useful for generating immune responses to Mycobacterium tuberculosis and for diagnosing infection and disease in a subject that has been exposed to M. tuberculosis.

公开(公告)号：US20170268055A1

公开(公告)日：2017-09-21

申请号：US15606354

申请日：2017-05-26

申请人： Illumina, Inc.

发明人： Eric Stava ,  Jens H. Gundlach ,  Jeffrey G. Mandell ,  Kevin L. Gunderson ,  Ian M. Derrington ,  Hosein Mohimani

IPC分类号： C12Q1/68 ,  C07K14/35 ,  G01N27/447

CPC分类号： C12Q1/6869 ,  C07K14/35 ,  G01N27/447 ,  C12Q2521/513 ,  C12Q2565/631

摘要： Methods and compositions for characterizing a target polynucleotide, including, characterizing the sequence of the target polynucleotide, using the fractional translocation steps of the target polynucleotide's translocation through a pore.

公开(公告)号：US09689033B2

公开(公告)日：2017-06-27

申请号：US14554741

申请日：2014-11-26

申请人： Illumina, Inc.

发明人： Eric Stava ,  Jens H. Gundlach ,  Jeffrey G. Mandell ,  Kevin L. Gunderson ,  Ian M. Derrington ,  Hosein Mohimani

IPC分类号： C12Q1/68 ,  G01N27/00 ,  C12M1/34 ,  C12Q1/34 ,  G01N27/447 ,  C07K14/35

CPC分类号： C12Q1/6869 ,  C07K14/35 ,  G01N27/447 ,  C12Q2521/513 ,  C12Q2565/631

摘要： Methods and compositions for characterizing a target polynucleotide, including, characterizing the sequence of the target polynucleotide, using the fractional translocation steps of the target polynucleotide's translocation through a pore.

公开(公告)号：US09624277B2

公开(公告)日：2017-04-18

申请号：US13877304

申请日：2011-09-30

申请人： Anil Suri ,  Deepika Kanojia ,  Prabhakar Salunkhe ,  Sidharth Mahali ,  Sunil Kumar Manna ,  Avadhesha Surolia ,  Ananda Chakrabarty

发明人： Anil Suri ,  Deepika Kanojia ,  Prabhakar Salunkhe ,  Sidharth Mahali ,  Sunil Kumar Manna ,  Avadhesha Surolia ,  Ananda Chakrabarty

IPC分类号： C07K14/45 ,  C07K14/35 ,  A61K38/16

CPC分类号： C07K14/45 ,  A61K38/164 ,  C07K14/35

摘要： The present invention thus provides microbial products as anticancer agents and pharmaceutical compositions comprising isolated and purified proteins or synthetic peptides, and methods of using them for the treatment of cancer. It is very important to develop new anticancer bioactive peptides having high activity and low toxicity; given that most currently available anticancer therapies either have significant toxicity, and/or are prone to development of resistance.